Regulus Therapeutics drug farabursen is a potential first-in-class treatment for a rare kidney disease whose only FDA-approved therapy introduces severe toxicity risks. Farabursen is joining a Novartis drug lineup spanning several therapies for rare renal disorders.
The post Novartis Gets Phase 3-Ready Rare Kidney Disease Drug via $800M Regulus Acquisition appeared first on MedCity News.
